


This article was downloaded by:

On: 26 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597286>

A Versatile Synthesis of Dihydropyrimidinone C-Nucleosides

Ram Chandra Mishra^a; Diksha Katiyar^a; Neetu Tewari^a; Rama Pati Tripathi^a

^a Medicinal Chemistry Division, Central Drug Research Institute, Lucknow, India

Online publication date: 03 December 2004

To cite this Article Mishra, Ram Chandra , Katiyar, Diksha , Tewari, Neetu and Tripathi, Rama Pati(2004) 'A Versatile Synthesis of Dihydropyrimidinone C-Nucleosides', *Nucleosides, Nucleotides and Nucleic Acids*, 23: 3, 531 — 544

To link to this Article: DOI: 10.1081/NCN-120030712

URL: <http://dx.doi.org/10.1081/NCN-120030712>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

A Versatile Synthesis of Dihydropyrimidinone C-Nucleosides

Ram Chandra Mishra, Diksha Katiyar, Neetu Tewari,
and Rama Pati Tripathi*

Medicinal Chemistry Division, Central Drug Research Institute, Lucknow, India

ABSTRACT

A versatile synthesis of *N*-substituted dihydropyrimidinone *C*-nucleosides (**20–29**) is described. Glycosyl amino esters (**3–9**), obtained by reductive alkylation of glycosyl amino esters **1** and **2**, on condensation with different isocyanates afforded respective ureido derivatives (**10–19**) in good to quantitative yields. The latter on cyclative amidation with a combination of DBU/TBAB (tetrabutylammonium bromide)/4Å molecular sieve gave the corresponding nucleosides (**20–29**) in good yields.

Key Words: Glycosyl amino esters; Isocyanates; DBU; TBAB (tetrabutylammonium bromide); *C*-nucleosides.

INTRODUCTION

Dihydropyrimidinones have been used as reagents and chiral auxiliaries in asymmetric synthesis of β -amino acids and many other biologically important compounds.^[1,2] *C*-Nucleosides, having a *C–C* linkage instead of a *C–N* linkage between the aglycon and sugar moiety are more stable towards the enzymatic degradation and

*Correspondence: Rama Pati Tripathi, Medicinal Chemistry Division, Central Drug Research Institute, Lucknow-226001, India; Fax: 0522-223938, 223405; E-mail: rpt_56@yahoo.com.

therefore the half-life of these compounds is far greater than that of nucleosides. Further, these nucleosides are associated with anticancer,^[3] antibacterial,^[4–6] antiviral^[7] and antileukemic activities.^[8–10] In spite of so much importance, no serious attempt has been made for the last two decades to synthesize dihydropyrimidinone *C*-nucleosides. Several reports exist for the synthesis of *C*-nucleosides.^[11–13] Prominent among these are reactions of suitably protected sugars or tetrahydrofuranaldehydes with metalated bases and to build heterocycles on preformed sugar derivatives.^[14–17] Reports on the synthesis of tetrahydropyrimidinone heterocycles by cyclisation of D-or L-asparagine and other β -amino acids with aldehydes also exist.^[18] Reported methods for the synthesis of *C*-nucleosides are difficult to perform and unsuitable for large-scale synthesis because of low yields and high cost.

In continuation of our recent work on the development of biologically active nucleosides^[19–23] the present work describes the synthesis of different dihydropyrimidinone *C*-nucleosides having N^1 and N^3 substituents.

RESULTS AND DISCUSSION


The synthetic strategy (Scheme 1) begins with glycosylated amino esters **1** and **2** prepared by our earlier method.^[19,20] Thus, ethyl 5-amino-5,6-dideoxy-1,2-*O*-isopropylidene-3-*O*-methyl- β -L-*ido*-hepto-1,4-furanuronate (**1**) on reaction with benzaldehyde in a mixture of dichloromethane and trimethyl orthoformate followed by in situ reduction with sodium cyanoborohydride, gave corresponding N-benzyl derivative **3** in very good yield. Similarly, glycosyl amino esters **4–9** were prepared by reductive alkylation of **1** and **2** in fair to good yields. Addition of 4-chlorophenyl isocyanate to compound **3** gave the corresponding 5-ureido-heptofuranuronate **10** in 95% yield.

Similarly, ureidoheptofuranuronates **11–19** were prepared by addition of substituted phenyl isocyanates to the glycosyl amino esters **4–9** in almost quantitative yields. The structures of ureido derivatives were determined on the basis of their spectroscopic data and elemental analysis. The ureido derivative **10** on heating with a combination of DBU/TBAB/4Å molecular sieve in refluxing toluene afforded 6-glycosyl dihydrouracil (**20**) in 90 % yield. Similarly dihydrouracil *C*-nucleosides (**21–29**) were obtained on reaction of ureidoheptofuranuronates (**11–19**) with the above cycloamidative reagent in refluxing toluene in respectable yields.

Configuration at C-5 in the ureidosugars and that of C-6 in the nucleosides is always that of the starting amino esters used. The relative configuration at C-5 in the furanosylated amino esters **1** and **2** has already been established^[19,20,24] to be 'S' based on Felkin-Anh transition state models and ¹H NMR spectrum. Since urea formation is simple addition of isocyanates to the amines, the configuration at the carbon linked to nitrogen does not change in this reaction. Further nucleoside formation does not involve C-5 and therefore the configuration at that centre is also unchanged.

In conclusion, we have developed an efficient and stereo-controlled synthesis of dihydropyrimidinone *C*-nucleosides. The method involves addition of isocyanates to the glycosyl amino esters followed by cyclization of glycosyl β -ureido esters with DBU/4Å molecular sieve and TBAB in refluxing toluene. The method is simple and applicable to synthesize a variety of *C*-nucleosides with well-defined stereochemistry.





Scheme 1. Synthesis of C-glycosyl dihydropyrimidinones.

EXPERIMENTAL

General Methods. Thin-layer chromatographies were carried out on silica gel (Kiesel 60-F254, Merck), spots were visualized in iodine vapours and also by spraying with 5% sulfuric acid in alcohol followed by heating at 100°C. Column chromatographies were carried out on silica gel (silica gel 60, 70–230 mesh, Merck) using the indicated eluent. IR spectra of liquids were recorded as thin films on KBr plates with a Perkin Elmer 881 spectrophotometer. NMR spectra were recorded on 200 MHz or 300 MHz Bruker spectrometers and CDCl₃ was used as the reference. Chemical shifts are given as δ values and '*J*' values are given in Hertz (Hz). Elemental analyses were performed on a Perkin–Elmer 2400 II elemental analyzer. The optical rotations were measured in a 1.0 dm tube with a Jasco dip-140 polarimeter in chloroform, methanol or



ethyl acetate. Excess of the reagents or solvents were evaporated under reduced pressure at a bath temperature between 45–55°C.

Ethyl[5-Benzylamino-5, 6-dideoxy]-1, 2-*O*-isopropylidene-3-*O*-methyl- β -L-ido-heptofuranuronate (3): Ethyl 5-amino-5, 6-dideoxy-1, 2-*O*-isopropylidene-3-*O*-methyl- β -L-ido-heptofuranuronate (1) (1.5 g, 4.10 mmol) was dissolved in a mixture of trimethyl orthoformate and dichloromethane (2:5) and stirred magnetically at 0°C. Benzaldehyde (0.7 mL, 6.15 mmol) was added and stirring continued for another 4h at the same temperature. NaCNBH₃ (0.25g, 4.1 mmol) was added to the stirring reaction mixture and stirring continued for 12h at 30°C. Solvent was evaporated under reduced pressure and the residue was dissolved in ethyl acetate and washed with aqueous NH₄Cl (2 × 25 mL) followed by water (2 × 20 mL). The organic layer was separated and dried (Na₂SO₄) and was evaporated under reduced pressure to give the crude mass, which was all chromatographed over SiO₂ using hexane: ethyl acetate (4:1) to give compound **3**, as colourless oil, yield 2.16g (85%); R_f 0.38 (5:1 hexane/ethyl acetate); [α]_D²⁰ –41.28 (c, 0.014, CH₃COOC₂H₅). MS (FAB): *m/z* 380 (M + H)⁺. IR (KBr), $\nu_{\max}$ cm^{–1}: 3355, 3048, 2978, 2923, 2845, 1721. ¹H NMR (CDCl₃): δ 7.34–7.31 (m, 5H, ArH), 5.90 (d, *J* = 3.7 Hz, 1H, H-1), 4.57 (d, *J* = 3.7 Hz, 1H, H-2), 4.23 (dd, *J* = 8.6 Hz and 3.1 Hz, 1H, H-4), 4.14 (q, *J* = 7.1 Hz, 2H, –OCH₂CH₃), 3.90 (d, *J* = 12 Hz, 1H, –NHCH_APh), 3.85 (d, *J* = 12 Hz, 1H, –NHCH_BPh), 3.73 (d, *J* = 3.1 Hz, 1H, H-3), 3.42–3.39 (m, 1H, H-5), 3.36 (s, 3H, –OCH₃), 2.55 (dd, *J* = 15.6 Hz and 4.7 Hz, 1H, H-6_A), 2.43 (dd, *J* = 15.6 Hz and 6.6 Hz, 1H, H-6_B), 2.02 (br s, 1H, –NHCH₂Ph), 1.47 and 1.30 [2 s, each 3H, C(CH₃)₂], 1.25 (t, *J* = 7.1 Hz, 3H, –OCH₂CH₃). ¹³C NMR (CDCl₃): δ 172.1 (C = O), 140.9, 128.7, 127.2 (Ar-C) 111.9 [C(CH₃)₂] 105.2 (C-1), 84.6 (C-2) 82.8 (C-4), 81.6 (C-3), 60.8 (–OCH₂CH₃), 57.6 (–OCH₃), 54.3 (C-5), 51.9 (–NCH₂), 36.9 (C-6), 27.1 and 26.9 [C(CH₃)₂], 14.62 (CH₃). Anal. Calcd for C₂₀H₂₉NO₆: C, 63.32; H, 7.65; N, 3.69. Found: C, 63.57; H, 7.83; N, 3.60.

Ethyl[5,6-Dideoxy-5-(4-methoxybenzyl amino)]-1,2-*O*-isopropylidene-3-*O*-methyl- β -L-ido-heptofuranuronate (4): Colourless oil, Yield 2.4 g (85 %), R_f 0.60 (3:2 hexane/ethyl acetate). [α]_D²⁰ –25.90 (c 0.2625, CHCl₃). MS (FAB): *m/z* 410 (M + H)⁺. IR (KBr), $\nu_{\max}$: 3341, 2983, 1730, 1247, 1177, 1028, 757 cm^{–1}. ¹H NMR (CDCl₃): δ 7.23 and 6.83 (2 d, *J* = 8.6 Hz, each 2H, ArH), 5.86 (d, *J* = 3.8 Hz 1H, H-1), 4.56 (d, *J* = 3.8 Hz, 1H, H-2), 4.18–4.07 (m, 4H, H-4, NCH_A and –OCH₂), 3.83–3.74 (m, 6H, –NCH_B, H-3, Ar–OCH₃ and H-5), 3.40 (s, 3H, OCH₃), 2.77–2.52 (m, 2 H, H-6) 1.67 (br s, 1H, –NH) 1.47 and 1.31 [2 s, each 3H, C(CH₃)₂], 1.24 (t, *J* = 7.1 Hz, 3H, –OCH₂CH₃). ¹³C NMR (CDCl₃): δ 172.8 (C = O) 159.0, 133.3, 129.6 114.1, (Ar-C) 111.9 [C(CH₃)₂], 105.1 (C-1), 84.2 (C-2), 82.2 (C-4), 81.8 (C-3), 60.6 (–OCH₂CH₃), 58.0 (Ar–OCH₃), 55.6 (–OCH₃), 52.5 (C-5), 51.3 (–NCH₂), 36.6 (C-6), 27.1 and 26.7 [C(CH₃)₂]and 14.64 (CH₃). Anal. Calcd for C₂₁H₃₁NO₇: C, 61.61; H, 7.58; N, 3.42. Found: C, 61.84; H, 7.72; N, 3.31.

Ethyl[5-(2-Chlorobenzylamino)-5,6-dideoxy]-1,2-*O*-isopropylidene-3-*O*-methyl- β -L-ido-heptofuranuronate (5): Colourless oil, Yield 3.0 g (70 %), R_f 0.70 (3:2 hexane/ethyl acetate). [α]_D²⁰ –40.00 (c 0.225,CHCl₃). MS (FAB): *m/z* 415 (M + H)⁺, IR(KBr), $\nu_{\max}$: 3355, 3048, 2978, 2923, 2845,1721 cm^{–1}. ¹H NMR (CDCl₃): δ 7.44 (d, *J* = 6.7 Hz, 1H, ArH), 7.33–7.16 (m, 3H, ArH), 5.91 (d, *J* = 3.6 Hz, 1H, H-1), 4.58 (d,



$J = 3.6$ Hz, 1H, H-2), 4.24 (dd, $J = 8.2$ Hz and 2.8 Hz, 1H, H-4), 4.13 (q, $J = 7.1$ Hz, 2H, $-\text{OCH}_2\text{CH}_3$), 3.96 (s, 2H, $-\text{NCH}_2$), 3.74 (d, $J = 2.8$ Hz, 1H, H-3), 3.45–3.43 (m, 1H, H-5), 3.36 (s, 3H, $-\text{OCH}_3$), 2.61–2.50 (m 2H, H-6), 1.86 (br s, 1H, $-\text{NH}$) 1.48 and 1.32 [2 s, each 3H, $\text{C}(\text{CH}_3)_2$], 1.25 (t, $J = 7.1$ Hz, 3H, $-\text{OCH}_2\text{CH}_3$). Anal. Calcd for $\text{C}_{20}\text{H}_{28}\text{NO}_6\text{Cl}$: C, 58.04; H, 6.77; N, 3.38. Found: C, 58.32; H, 6.94; N, 3.11.

Ethyl[5,6-Dideoxy-5-(3,4-dimethoxybenzylamino)]-1,2-*O*-isopropylidene-3-*O*-methyl- β -L-ido-heptofuranuronate (6): Colourless oil, Yield 2.58 g (85 %), R_f 0.45 (3:2 hexane/ethyl acetate). $[\alpha]_D^{20} -40.21$ (c 0.4625, $\text{CH}_3\text{COOC}_2\text{H}_5$). MS (FAB): m/z 440 ($\text{M} + \text{H}^+$). IR (KBr), ν_{max} : 3343, 2985, 2368, 1731, 1514, 1261, 857, 756 cm^{-1} . ^1H NMR (CDCl_3): δ 6.89–6.73 (m, 3H, ArH), 5.88 (d, $J = 3.8$ Hz, 1H, H-1), 4.56 (d, $J = 3.8$ Hz, 1H, H-2), 4.23–4.07 (m, 3H, H-4 and $-\text{OCH}_2$), 3.87–3.77 (m, 8H, ArOCH_3 and NHCH_2), 3.70 (d, $J = 2.7$ Hz, 1H, H-3), 3.38–3.36 (m, 1H, H-5), 3.34 (s, 3H, $-\text{OCH}_3$), 2.52 (dd, $J = 16.8\text{Hz}$ and 5.2 Hz, 1H, H-6_A), 2.39 (dd, $J = 16.8\text{Hz}$ and 5.6 Hz, 1H, H-6_B), 1.97 (br s, 1H, $-\text{NH}$) 1.45 and 1.29 [2 s, each 3H, $\text{C}(\text{CH}_3)_2$], 1.23 (t, $J = 7.1$ Hz, 3H, $-\text{OCH}_2\text{CH}_3$). ^{13}C NMR (CDCl_3): δ 172.1 (C = O), 149, 148.3, 133.0, 120.6, 111.4, 112.7 (Ar-C), 111.9 [$\text{C}(\text{CH}_3)_2$], 105.1 (C-1), 84.5 (C-2), 82.8 (C-4), 81.5 (C-3), 60.7 ($-\text{OCH}_2\text{CH}_3$), 57.7 ($-\text{OCH}_3$), 56.3, 56.2 (Ar- OCH_3), 54.2 (C-5), 51.6 ($-\text{NCH}_2$), 36.8 (C-6), 27.1 and 26.6 [$\text{C}(\text{CH}_3)_2$], 14.6 (CH_3). Anal. Calcd for $\text{C}_{22}\text{H}_{33}\text{NO}_8$: C, 60.13; H, 7.51; N, 3.19. Found: C, 60.31; H, 7.68; N, 3.05.

Ethyl[3-*O*-Benzyl-5,6-dideoxy-1,2-*O*-isopropylidene]-5-(4-methoxybenzylamino)- β -L-ido-heptofuranuronate (7): Colourless oil, Yield 2.25 g (86 %), R_f 0.38 (5:1 hexane/ethyl acetate). $[\alpha]_D^{20} -15.46$ (c 0.37, CHCl_3). MS (FAB): m/z 486 ($\text{M} + \text{H}^+$). IR (KBr), ν_{max} : 3339, 2987, 2431, 1729, 1612, 1513, 1378, 1248, 1078, 758 cm^{-1} . ^1H NMR (CDCl_3): δ 7.31–7.25 (m, 5H, ArH), 7.21 and 6.81 (2 d, $J = 8.4$ Hz, each 2H, ArH), 5.94 (d, $J = 3.8$ Hz, 1H, H-1), 4.69 and 4.44 (2 d, $J = 11.7$ Hz, each 1H, $-\text{OCH}_A$ and OCH_B), 4.63 (d, $J = 3.8$ Hz, 1H, H-2), 4.23 (dd, $J = 9.6$ and 3.0 Hz, 1H, H-4), 4.10 (q, $J = 7.1$ Hz, 2H, OCH_2), 3.99 (d, $J = 3.0$ Hz, 1H, H-3) 3.80–3.77 (m, 5H, $-\text{NHCH}_2$ and Ar- OCH_3), 3.52–3.48 (m, 1H, H-5), 2.42–2.31 (m, 2H, H-6), 1.95 (br s, 1H, $-\text{NH}$), 1.47 and 1.32 [2 s, each 3H, $\text{C}(\text{CH}_3)_2$], 1.22 (t, $J = 7.1$ Hz, 3H, $-\text{OCH}_2\text{CH}_3$). ^{13}C NMR (CDCl_3): δ 172.1 (C = O), 137.4, 133.0, 131.9, 131.7, 129.8, 129.0, 128.8, 128.5, 128.4, 128.2, 127.3, 114.1 (Ar-C), 112.0 [$\text{C}(\text{CH}_3)_2$], 105.2 (C-1), 82.6 (C-2), 82.2 (C-4), 82.1 (C-3), 71.9 ($-\text{OCH}_2\text{Ph}$), 60.8 ($-\text{OCH}_2\text{CH}_3$), 55.6 (Ar- OCH_3), 54.1 (C-5), 51.4 ($-\text{NCH}_2$), 36.8 (C-6), 27.1 and 26.7 [$\text{C}(\text{CH}_3)_2$], 14.6 (CH_3). Anal. Calcd for $\text{C}_{27}\text{H}_{35}\text{NO}_7$: C, 66.80; H, 7.21; N, 2.88. Found: C, 66.97; H, 7.37; N, 2.82.

Ethyl[3-*O*-Benzyl-5-(2-chlorobenzylamino)]-5,6-dideoxy-1,2-*O*-isopropylidene- β -L-ido-heptofuranuronate (8): Colourless oil, Yield 2.1 g (74 %), R_f 0.65 (3:2 hexane/ethyl acetate). $[\alpha]_D^{20} -20.32$ (c 0.7625, CHCl_3). MS (FAB): m/z 491 ($\text{M} + \text{H}^+$). IR (KBr), ν_{max} : 2984, 1731, 1454, 1377, 1216, 1078, 754 cm^{-1} . ^1H NMR (CDCl_3): δ 7.42 – 7.22 (m, 7H, ArH), 7.18 – 7.14 (m, 2H, ArH), 5.95 (d, $J = 3.7$ Hz 1H, H-1), 4.68 and 4.44 (2 d, $J = 11.8$ Hz, each 1H, $-\text{OCH}_A$ and OCH_B), 4.63 (d, $J = 3.7$ Hz, 1H, H-2), 4.25 (dd, $J = 8.6$ and 2.7 Hz, 1H, H-4), 4.07 (q, $J = 7.1$ Hz, 2H, OCH_2), 3.94 (s, 3H, NHCH_2 and H-3), 3.54–3.49 (m, 1H, H-5), 2.56 (dd, $J = 10.7$ Hz and 4.5 Hz, each 1H, H-6_A), 2.39 (dd, $J = 10.7$ Hz and 4.5 Hz, each 1H, H-6_B), 1.96 (br s, 1H, $-\text{NH}$) 1.48 and 1.31 [2 s, each 3H, $\text{C}(\text{CH}_3)_2$], 1.20 (t, $J = 7.1$ Hz, 3H, $-\text{OCH}_2\text{CH}_3$). ^{13}C NMR



(CDCl₃): δ 172.1 (C = O), 138.5, 137.5, 134.1, 130.5, 129.7, 128.9, 128.4, 127.1 (Ar-C), 112.0 [C(CH₃)₂], 105.3 (C-1), 82.7 (C-2), 82.2 (C-4), 74.9 (C-3), 71.9 (–OCH₂Ph), 60.8 (–OCH₂CH₃), 54.1 (C-5), 49.2 (–NCH₂), 36.8 (C-6), 27.2 and 26.7 [C(CH₃)₂], 14.6 (CH₃). Anal. Calcd for C₂₆H₃₂NO₆Cl: C, 63.73; H, 6.53; N, 2.86. Found: C, 63.91; H, 6.72; N, 2.78.

Ethyl[3-*O*-Benzyl-5,6-dideoxy-5-(3,4-dimethoxybenzylamino)]-1,2-*O*-isopropylidene- β -L-ido-heptofuranuronate (9): Colourless oil; yield 2.64 g (85 %), R_f 0.65 (3:2 hexane/ethyl acetate), $[\alpha]_D^{20}$ –32.0 (c 0.225, CHCl₃), MS (FAB): m/z 517 (M + H)⁺, IR (KBr), $\nu_{\max}$: 3355, 3048, 2978, 2923, 2845, 1721, 1207, 1078, 752 cm^{–1}. ¹H NMR (CDCl₃): δ 7.31–7.28 (m, 5H, ArH), 6.81–6.75 (m, 3H, ArH), 5.90 (d, J = 3.8 Hz 1H, H-1), 4.68 and 4.53 (2 d, J = 11.7 Hz, each 1H, –OCH_A and OCH_B), 4.60 (d, J = 3.8 Hz, 1H, H-2), 4.21–4.07 (m, 4H, –NHCH_A, H-4 and –OCH₂), 3.84 and 3.82 (2 s, each 3 H, ArOCH₃), 3.75–3.64 (m, 2H, –NHCH_B and H-3), 3.64–3.61 (m, 1H, H-5), 2.82 (dd, J = 16.8 Hz and 4.2 Hz, 1H, H-6_A), 2.56 (dd, J = 16.8 Hz and 6.70 Hz, 1H, H-6_B), 1.61 (br s, 1H, –NH) 1.47 and 1.31 [2 s, each 3H, C(CH₃)₂], 1.24 (t, J = 7.1 Hz, 3H, –OCH₂CH₃). ¹³C NMR (CDCl₃): δ 173.0 (C = O), 150.2, 149.2, 138.4, 134.6, 129.8, 129.3, 128.9, 121.6, 113.1 (Ar-C), 112.7 [C(CH₃)₂], 106.2 (C-1), 83.6 (C-2), 83.1 (C-4), 83.0 (C-3), 72.8 (–OCH₂Ph), 61.6 (–OCH₂CH₃), 57.2, 57.1 (Ar–OCH₃), 54.9 (–NCH₂) 52.6 (C-5), 37.7 (C-6), 28.0 and 27.6 [C(CH₃)₂], 15.5 (CH₃). Anal. Calcd for C₂₈H₃₇NO₈: C, 65.24; H, 7.18; N, 2.71. Found: C, 64.89; H, 7.35; N, 2.69.

Ethyl 5-[*N*-Benzyl-*N'*-(4-chlorophenyl)ureido]5,6-dideoxy-1,2-*O*-isopropylidene-3-*O*-methyl- β -L-ido-heptofuranuronate (10) General Procedure: The above amino ester **3** (1.0 g, 2.64 mmol) and 4-chlorophenyl isocyanate (0.407g, 2.65 mmol) in anhydrous dichloromethane (15.0 ml) were magnetically stirred at 25°C temperature for 2 h. Solvent was evaporated and the reaction mixture was chromatographed over a SiO₂ column using a gradient of hexane: ethyl acetate (3:2) as eluent to give compound **10** as colourless foam; 1.48 g (95 %). R_f 0.40 (3:2 hexane/ethyl acetate), $[\alpha]_D^{20}$ –44.0 (c 0.2, CHCl₃). MS (FAB): m/z 534 (M + H)⁺. IR (Neat) $\nu_{\max}$: 3370, 3306, 2926, 2372, 1712, 1665, 1602, 1546, 1212, 1078, 717 cm^{–1}. ¹H NMR (CDCl₃): δ 7.42–7.34 (m, 9H, ArH), 5.97 (d, J = 3.8 Hz, 1H, H-1), 4.86 and 4.24 (2 d, J = 15.3 Hz, each 1H, NCH_A and –NCH_B), 4.66 (d, J = 3.8 Hz, 1H, H-2), 4.44–4.40 (m, 2H, H-4, H-5), 4.08 (q, J = 7.1 Hz, 2H, –OCH₂), 3.63 (d, J = 2.8 Hz, 1H, H-3), 3.39 (s, 3H, –OCH₃), 2.82–2.76 (m, 1H, H-6_A), 2.47 (dd, J = 15.7 and 3.6 Hz, 1H, H-6_B), 1.47 and 1.31 [2 s, each 3H, C(CH₃)₂] 1.24 (t, J = 7.1 Hz, 3H, –OCH₂CH₃). ¹³C NMR (CDCl₃): δ 172.3 (C = O), 157.8 (NHCO), 129.2, 129.1, 122.3 (Ar-C), 112.2 [C(CH₃)₂], 105.0 (C-1), 84.3 (C-2), 81.3 (C-4), 79.7 (C-3), 61.4 (–OCH₂CH₃), 57.1 (–OCH₃), 34.9 (C-6), 27.1 and 26.5 [C(CH₃)₂], 14.4 (CH₃). Anal. Calcd for C₂₇H₃₃N₂O₇Cl: C, 60.84; H, 6.19; N, 5.25 Found: C, 60.72; H, 6.43; N, 5.14.

Ethyl 5-[*N*-(2-Chlorobenzyl)-*N'*-phenylureido]-5,6-dideoxy-1,2-*O*-isopropylidene-3-*O*-methyl- β -L-ido-heptofuranuronate (11): Colourless foam; yield 0.48g (95 %), R_f 0.55 (3:2 hexane/ethyl acetate), $[\alpha]_D^{20}$ –92.0 (c 0.05, CHCl₃). MS (FAB) m/z = 436. IR (Neat) $\nu_{\max}$: 3342, 1717, 1670, 1543, 1079, 1022, 889, 755 cm^{–1}. ¹H NMR (CDCl₃): δ 8.41 (bs, 1H, NH), 7.47–6.98 (m, 9 H, ArH), 5.85 (d, J = 3.7 Hz, 1H, H-1), 4.97 and 4.47 (2 d, J = 16.3 Hz, each 1H, –NCH_APh and –NCH_BPh), 4.73–4.65 (m, 1H,

H-5), 4.52 (d, $J = 3.7$ Hz, 1H, H-2), 4.24 (dd, $J = 6.34$ and 2.8 Hz, 1H, H-4), 4.10 (q, $J = 7.1$ Hz, 2H, $-\text{OCH}_2$), 3.45 (d, $J = 2.8$ Hz, 1H, H-3), 3.31 (s, 3H, OCH_3), 2.91 (dd, $J = 17.4$ and 3.2 Hz, 1H, H-6_A), 2.70 (dd, $J = 17.4$ and 11.5 Hz, 1H, H-6_B), 1.44 and 1.29 [2 s, each 3H, $\text{C}(\text{CH}_3)_2$], 1.17 (t, $J = 7.1$ Hz, 3H, $-\text{OCH}_2\text{CH}_3$). Anal. Calcd for $\text{C}_{27}\text{H}_{33}\text{N}_2\text{O}_7\text{Cl}$: C, 60.84; H, 6.19; N, 5.25. Found: C, 61.03; H, 6.04; N, 5.39.

Ethyl 5-[N-(2-Chlorobenzyl)-N'-(4-chlorophenyl)ureido]-5,6-dideoxy-1,2,-O-isopropylidene-3-O-methyl- β -L-ido-heptofuranuronate (12): Colourless foam; yield 1.04 g (96 %), R_f 0.50 (3:2 hexane/ethyl acetate), $[\alpha]_D^{20} -50.0$ (c 0.150, CHCl_3). MS (FAB): m/z 568 ($\text{M} + \text{H}^+$). IR (Neat) $\nu_{\max}$: 2996, 2405, 1723, 1668, 1529, 1384, 1222, 1084, 1052, 759, 688 cm^{-1} . ^1H NMR (CDCl_3): δ 7.80 (br s, 1H, NH), 7.45 (d, $J = 6.7$ Hz, 1H, ArH), 7.34–7.13 (m, 7H, ArH), 5.91 (d, $J = 3.7$ Hz, 1H, H-1), 4.83–4.62 (m, 3H, $-\text{NCH}_A\text{Ph}$, $-\text{NCH}_B\text{Ph}$ and H-5), 4.61 (d, $J = 3.7$ Hz, 1H, H-2), 4.35–4.32 (m, 1H, H-4), 4.11 (q, $J = 7.1$ Hz, 2H, $-\text{OCH}_2$), 3.60 (d, $J = 2.9$ Hz, 1H, H-3), 3.39 (s, 3H, OCH_3), 2.67 (dd, $J = 16.4$ and 9.8 Hz, 1H, H-6_A), 2.70 (dd, $J = 16.4$ and 3.7 Hz, 1H, H-6_B), 1.36 and 1.30 [2 s, each 3H, $\text{C}(\text{CH}_3)_2$], 1.20 (t, $J = 7.1$ Hz, 3H, $-\text{OCH}_2\text{CH}_3$). Anal. Calcd for $\text{C}_{27}\text{H}_{32}\text{N}_2\text{O}_7$: C, 57.14; H, 5.64; N, 4.93. Found: C, 57.22; H, 5.69; N, 4.76.

Ethyl 5-[N-(4-Methoxybenzyl)-N'-benzylureido]-5,6-dideoxy-1,2,-O-isopropylidene-3-O-methyl- β -L-ido-heptofuranuronate (13): Colourless foam; Yield 1.25 g (95 %), R_f 0.40 (3:2 hexane/ethyl acetate), $[\alpha]_D^{20} -54.66$ (c 0.150, CHCl_3). MS (FAB): m/z 543 ($\text{M} + \text{H}^+$). IR (Neat) $\nu_{\max}$: 3428, 2989, 2386, 1730, 1646, 1517, 1246, 1081, 759 cm^{-1} . ^1H NMR (CDCl_3): δ 7.29–7.13 (m, 7H, ArH), 6.81 (d, $J = 8.6$ Hz, 2H, ArH), 5.88 (d, $J = 3.8$ Hz, 1H, H-1), 5.10 (br s, 1H, NH), 4.58 (d, $J = 3.8$ Hz, 1H, H-2), 4.52–4.44 (m, 4H, NCH_2 , H-5 and H-4), 4.36 (d, $J = 5.3$ Hz, 2H, $-\text{NHCH}_2$), 4.08 (q, $J = 7.1$ Hz, 2H, $-\text{OCH}_2$), 3.77 (s, 3H, Ar- OCH_3), 3.58 (d, $J = 2.2$ Hz, 1H, H-3), 3.34 (s, 3H, OCH_3), 2.80 (m, 1H, H-6_A), 2.42 (dd, $J = 15.5$ and 3.7 Hz, 1H, H-6_B), 1.39 and 1.30 [2 s, each 3H, $\text{C}(\text{CH}_3)_2$], 1.19 (t, $J = 7.1$ Hz, 3H, $-\text{OCH}_2\text{CH}_3$). ^{13}C NMR (CDCl_3): δ 171.6 (C = O), 159.5 (NHC = O), 159.2, 140.2, 131.3, 128.6, 128.6, 127.6, 127.2, 114.5 (Ar-C), 112.1 [$\text{C}(\text{CH}_3)_2$], 105.0 (C-1), 84.2 (C-2), 81.2 (C-4), 80.1 (C-3), 61.2 ($-\text{OCH}_2\text{CH}_3$), 57.6 (Ar- OCH_3), 55.6 ($-\text{OCH}_3$), 45.1 ($-\text{NCH}_2$), 36.1 (C-6), 27.1 and 26.8 [$\text{C}(\text{CH}_3)_2$], 14.5 (CH_3). Anal. Calcd for $\text{C}_{29}\text{H}_{38}\text{N}_2\text{O}_8$: C, 64.20; H, 7.01; N, 5.16. Found: C, 64.48; H, 7.33; N, 4.97.

Ethyl 5,6-Dideoxy-5-[N-(3,4-dimethoxybenzyl)-N'-phenylureido]-1,2,-O-isopropylidene-3-O-methyl- β -L-ido-heptofuranuronate (14): Colourless foam; yield 1.20 g (95 %), R_f 0.35 (3:2 hexane/ethyl acetate), $[\alpha]_D^{20} -11.5$ (c 0.40, CHCl_3). MS (FAB): m/z 559 ($\text{M} + \text{H}^+$). IR (Neat) $\nu_{\max}$: 3343, 2938, 2838, 1720, 1667, 1601, 1518, 1450, 1254, 1080, 1023, 756 cm^{-1} . ^1H NMR (CDCl_3): δ 8.10 (br s, 1H, NH), 7.43–7.39, 7.29–7.21, 6.97–6.87, 6.81–6.78 (4 m, each 2 H, ArH), 5.86 (d, $J = 3.8$ Hz, 1H, H-1), 4.75 and 4.37 (2 d, $J = 15.0$ Hz, each 1H, NCH_A and NCH_B), 4.50 (d, $J = 3.8$ Hz, 1H, H-2), 4.24 (dd, $J = 7.9$ and 3.1 Hz, 1H, H-4), 4.18–4.04 (m, 3H, $-\text{OCH}_2$ and H-5), 3.84 and 3.83 (2 s, each 3H, Ar- OCH_3), 3.50 (d, $J = 3.1$ Hz, 1H, H-3), 3.31 (s, 3H, OCH_3), 2.85 (dd, $J = 16.8$ and 3.2 Hz, 1H, H-6_A), 2.81 (dd, $J = 16.8$ and 10.0 Hz, 1H, H-6_B), 1.43 and 1.29 [2 s, each 3H, $\text{C}(\text{CH}_3)_2$], 1.19 (t, $J = 7.1$ Hz, 3H, $-\text{CH}_2\text{CH}_3$). ^{13}C NMR (CDCl_3): δ 173.3 (C = O), 157.2 (NHC = O), 149.6, 148.7, 140.3, 132.4, 129.2,



122.6, 120.2, 119.4 (Ar-C), 112.2 [C(CH₃)₂], 111.6, 111.4 (Ar-C), 105.3 (C-1), 84.3 (C-2), 81.5 (C-4), 80.7 (C-3), 61.5 (–OCH₂CH₃), 58.10 (–OCH₃), 56.3, 56.3 (Ar–OCH₃), 53.80 (C-5), 35.9 (C-6), 27.1 and 26.5 [C(CH₃)₂], 14.6 (CH₃). Anal. Calcd for C₂₉H₃₈N₂O₉: C, 62.36; H, 6.81; N, 5.01. Found: C, 62.48; H, 6.44; N, 4.81.

Ethyl 5[*N'*-Benzyl-*N*-(3,4-dimethoxybenzyl)ureido]-5,6-dideoxy-1,2,-*O*-isopropylidene-3-*O*-methyl-β-*L*-ido-heptofuranuronate (15): Colourless foam, yield 1.23 g (96 %), R_f 0.40 (3:2 hexane/ethyl acetate), [α]_D²⁰ –23.29 (c 0.85, CHCl₃). MS (FAB): *m/z* 573 (M + H)⁺. IR (Neat) ν_{max}: 3404, 2989, 2368, 1730, 1646, 1519, 1259, 856, 755, 599 cm^{–1}. ¹H NMR (CDCl₃): δ 7.27–7.16 (m, 3H, ArH), 7.11–7.09 (m, 2H, ArH), 6.77–6.74 (m, 3H, ArH), 5.86 (d, *J* = 3.7 Hz, 1H, H-1), 5.13 (br s, 1H, NH), 4.58 (d, *J* = 3.7 Hz, 1H, H-2), 4.49–4.28 (m, 5H, –NCH₂, –NHCH₂ and H-5), 4.14–4.04 (m, 3H, H-4, and –OCH₂), 3.83 and 3.81 (2 s, each 3H, ArOCH₃), 3.58 (s, 1H, H-3), 3.35 (s, 3H, OCH₃), 2.94–2.86 (m, 1H, H-6_A), 2.44 (dd, *J* = 15.3 and 3.1 Hz, 1H, H-6_B), 1.35 and 1.29 [2 s, each 3H, C(CH₃)₂], 1.24 (t, *J* = 7.3 Hz, 3H, OCH₂CH₃). ¹³C NMR (CDCl₃): δ 171.7 (C = O), 159.3 (NHC = O), 149.9, 148.6, 140.10, 131.8, 128.9, 128.7, 127.9, 127.8, 127.5, 127.4, 127.1, 118.9, 112.2 (Ar-C), 112.0 [C(CH₃)₂], 111.4, 111.2, 110.8 (Ar-C), 105.1 (C-1), 84.1 (C-2), 81.5 (C-4), 80.1 (C-3), 61.2 (–OCH₂CH₃), 57.7 (–OCH₃), 56.3, 56.2 (Ar–OCH₃), 45.4 (–NCH₂), 36.7 (C-1), 27.1 and 26.8 [C(CH₃)₂], 14.6 (CH₃). Anal. Calcd for C₃₀H₄₀N₂O₉: C, 62.93; H, 6.99; N, 4.89. Found: C, 61.8; H, 7.08; N, 4.63.

Ethyl 3-*O*-Benzyl-5-[*N*-(2-chlorobenzyl)-*N'*-phenylureido]-5,6-dideoxy-1,2,-*O*-isopropylidene-β-*L*-ido-heptofuranuronate (16): Colourless foam, yield 1.1 g (90 %), R_f 0.45 (3:2 hexane/ethyl acetate), [α]_D²⁰ –12.5 (c 0.2, CHCl₃). MS (FAB): *m/z* 610 (M + H)⁺. IR (Neat) ν_{max}: 3343, 2995, 2934, 2363, 1729, 1834, 1524, 1450, 1378, 1174, 1081, 1023, 853, 758 cm^{–1}. ¹H NMR (CDCl₃): δ 7.7 (br s, 1H, NH), 7.46–7.43 (m, 2H, ArH), 7.34–7.15 (m, 10H, ArH), 7.00–6.95 (m, 2H, ArH), 5.95 (d, *J* = 3.6 Hz, 1H, H-1), 4.86–4.54 (m, 5H, –OCH₂Ph, H-2, –NCH₂ and H-5), 4.40 (d, *J* = 11.9 Hz, 1H, –OCH₂), 4.34–4.30 (m, 1H, H-4), 4.05 (q, *J* = 7.1 Hz, 2H, –OCH₂), 3.77 (s, 1H, H-3), 2.56–2.43 (m, 1H, H-6_A), 2.00 (dd, *J* = 16.5 and 2.4 Hz, 1H, H-6_B), 1.55 and 1.37 [2 s, each 3H, C(CH₃)₂], 1.25 (t, *J* = 7.14 Hz, 3H, –OCH₂CH₃). ¹³C NMR (CDCl₃): δ 171.8 (C = O), 157.7 (NHC = O), 140.1, 137.0, 136.7, 132.6, 129.7, 129.6, 129.3, 129.1, 128.8, 128.6, 127.5, 123.6, 120.2 (Ar-C), 111.9 [C(CH₃)₂], 105.2 (C-1), 82.2 (C-2), 80.9 (C-4), 79.5 (C-3), 71.8 (–OCH₂Ph), 61.5 (–OCH₂CH₃), 52.5 (–NCH₂), 34.8 (C-6), 27.2 and 26.8 [C(CH₃)₂], 14.5 (CH₃). Anal. Calcd for C₃₃H₃₇N₂O₇Cl : C, 65.07; H, 6.08; N, 4.60. Found: C, 65.36; H, 6.32; N, 4.34.

Ethyl 3-*O*-Benzyl-5-[*N'*-(4-chlorophenyl)-*N*-(4-methoxybenzyl)ureido]-5,6-dideoxy-1,2,-*O*-isopropylidene-β-*L*-ido-heptofuranuronate (17): Colourless foam, yield 1.25g (%), R_f 0.40 (3:2 hexane/ethyl acetate) [α]_D²⁰ –13.81 (c 0.1375, CHCl₃). MS (FAB): *m/z* 640 (M + H)⁺. IR (Neat) ν_{max}: 2992, 2312, 1729, 1682, 1597, 1426, 1211, 870, 756 cm^{–1}. ¹H NMR (CDCl₃): δ 7.59 (bs, 1H, NH), 7.30–7.23 (m, 8H, ArH), 7.16 (s, 3H, ArH), 6.82(d, *J* = 8.54 Hz, 2H, ArH), 5.96 (d, *J* = 3.7 Hz, 1H, H-1), 4.72 and 4.40 (2 d, *J* = 11.7 Hz, each 1H, OCH_A and OCH_B), 4.66 (d, *J* = 3.7 Hz, 1H, H-2), 4.56–4.37 (m, 4H, N-CH₂, H-4 and H-5), 4.08 (q, *J* = 7.1 Hz, 2H, –OCH₂), 3.76 (s, 4H, –OCH₃ and H-3), 2.84–2.77 (m, 1H, H-6_A), 2.03 (dd, *J* = 16.7 and 2.2 Hz, 1H, H-6_B), 1.40, 1.31 [2 s, each 3H, C(CH₃)₂], 1.23 (t, *J* = 7.14 Hz, 3H, –OCH₂CH₃). ¹³C



NMR (CDCl₃): δ 171.9 (C = O), 159.2 (NHC = O), 139.1, 137.0, 128.2, 128.8, 128.7, 128.6, 121.1, 114.6 (Ar-C), 112.0 [C(CH₃)₂], 105.1 (C-1), 82.2 (C-2), 81.0 (C-4), 79.6 (C-3), 71.9 (–OCH₂Ph), 61.4 (–OCH₂CH₃), 55.6 (–NCH₂), 35.1 (C-6), 27.1 and 26.7 [C(CH₃)₂], 14.5 (CH₃). Anal. Calcd for C₃₄H₃₉N₂O₈Cl : C, 63.89; H, 6.10; N, 4.38. Found: C, 63.67; H, 6.35; N, 4.10.

Ethyl 3-*O*-Benzyl-5,6-dideoxy-5-[*N*-(3,4-dimethoxybenzyl)-*N'*-phenylureido]-1,2-*O*-isopropylidene- β -L-ido-heptofuranuronate (18): Colourless foam, yield 0.66 g (90 %), R_f 0.40 (3:2 hexane/ethyl acetate). [α]_D²⁰ –14.0 (*c* 0.05, CHCl₃). MS (FAB): *m/z* 658 (M + Na)⁺. IR (Neat) $\nu_{\max}$: 3408, 1718, 1658, 1516, 1232, 1077, 1025, 857, 756 cm^{–1}. ¹H NMR (CDCl₃): δ 7.31–6.98 (m, 10H, ArH), 6.84–6.76 (m, 3H, ArH), 5.96 (d, *J* = 3.8 Hz, 1H, H-1), 4.72 and 4.41 (2 d, *J* = 11.7 Hz, each 1H, OCH_APh and OCH_BPh), 4.68 (d, *J* = 3.8 Hz, 1H, H-2), 4.56–4.38 (m, 3H, NCH₂ and H-4), 4.12 (q, *J* = 7.1 Hz, 2H, OCH₂), 3.86 and 3.85 (2 s, each 3H, Ar–OCH₃), 3.78 (d, *J* = 2.3 Hz, 1H, H-3), 3.58–3.42 (m, 1H, H-5), 2.78–2.62 (m, 1H, H-6_A), 2.11 (d, *J* = 14.7 Hz, 1H, H-6_B), 1.39 and 1.27 [2 s, each 3H, C(CH₃)₂], 1.25 (t, *J* = 7.1 Hz, 3H, –OCH₂CH₃). Anal. Calcd for C₃₅H₄₂N₂O₉ : C, 66.24; H, 6.62; N, 4.41. Found: C, 66.85; H, 7.01; N, 4.02.

Ethyl x5-[*N'*-(3-Acetylphenyl)-*N*-(3,4-dimethoxybenzyl)ureido]-3-*O*-benzyl-5,6-dideoxy-1,2-*O*-isopropylidene- β -L-ido-heptofuranuronate (19): Colourless foam, yield 0.70 g (89 %), R_f 0.35 (3:2 hexane/ethyl acetate), [α]_D²⁰ –29.77 (*c* 0.225, CHCl₃). MS (FAB): *m/z* 677 (M + H)⁺. IR (Neat) $\nu_{\max}$: 3012, 2369, 1729, 1677, 1594, 1518, 1263, 1077, 898, 755 cm^{–1}. ¹H NMR (CDCl₃): δ 7.8 (bs, 1H, NH), 7.63–7.57 (m, 1H, ArH), 7.52–7.26 (m, 8H, ArH), 6.83–6.80 (m, 2H, ArH), 5.98 (d, *J* = 3.8 Hz, 1H, H-1), 4.74 and 4.40 (2 d, *J* = 11.9 Hz, each 1H, –OCH_APh and OCH_BPh), 4.68 (d, *J* = 3.8 Hz, 1H, H-2), 4.55 (s, 2H, NCH₂), 4.17–4.06 (m, 4H, H-4, H-5 and –OCH₂), 3.84 (s, 6H, Ar–OCH₃), 3.77 (d, *J* = 2.4 Hz, 1H, H-3), 2.57–2.55 (m, 5H, ArCOCH₃ and H-6), 1.37 and 1.31 [2 s, each 3H, C(CH₃)₂], 1.25 (t, *J* = 7.4 Hz, 3H, –OCH₂CH₃). Anal. Calcd for C₃₇H₄₄N₂O₁₀: C, 65.68; H, 6.50; N, 4.14. Found: C, 66.12; H, 7.08; N, 3.95.

General Procedure for the synthesis of compounds 20–29: (6*S*)-1-Benzyl-3-(4-chlorophenyl)-5,6-dihydro-6-(1,2-*O*-isopropylidene-3-*O*-methyl- α -D-xylo-tetrofuranos-4-yl)uracil (20): A mixture of compound **10** (0.3 g, 0.564 mmol), 4Å MS (0.03 g), TBAB (0.03 g, 0.093 mmol) and DBU (0.086 mL, 0.564 mmol) in anhydrous toluene (15 mL) was heated at reflux for 2 h. The solvent was evaporated and the residue was chromatographed over a SiO₂ column using a gradient of hexane: ethyl acetate (3:1) as eluent to give **20** as a colourless foam, yield 0.260 g (95 %). R_f 0.45 (3:2 Hexane/ethyl acetate), [α]_D²⁵ –17.77 (*c* 0.1125, CHCl₃). MS (FAB): *m/z* 488. IR (Neat) $\nu_{\max}$: 3450, 2937, 2376, 1678 1599, 1450, 1372, 1203, 1082, 1018, 704 cm^{–1}. ¹H NMR (CDCl₃): δ 7.41 (d, *J* = 8.4 Hz, 2 H, ArH), 7.34–7.30 (m, 5H, ArH), 7.11 (d, *J* = 8.4 Hz, 2 H, ArH), 5.98 (d, *J* = 3.6 Hz, 1H, H-1'), 5.40 and 4.28 (2 d, *J* = 15.3 Hz, each 1H, NCH_A and NCH_B), 4.61 (d, *J* = 3.6 Hz, 1H, H-2'), 4.44 (d, *J* = 9.3 Hz, 1H, H-4'), 3.87–3.82 (m, 1H, H-6), 3.70 (s, 1H, H-3'), 3.36 (s, 3H, OCH₃), 2.87 (dd, *J* = 16.8 and 6.6 Hz, 1H, H-5_A), 2.56 (d, *J* = 16.8 Hz, 1H, H-5_B), 1.49 and 1.34 [2 s, each 3H, C(CH₃)₂]. ¹³C NMR (CDCl₃): δ 168.1 (C = O), 157.6 (NC = ON), 157.1, 134.1, 133.8, 129.9, 129.2, 128.7, 128.2, 127.6 (Ar-C), 111.8 [C(CH₃)₂], 105.0 (C-1), 83.6 (C-2), 80.7 (C-4), 80.3 (C-3), 57.3

(–OCH₃), 51.4 (C-6), 49.7 (–NCH₂), 34.6 (C-5), 26.6 and 26.0 [C(CH₃)₂]. Anal. Calcd for C₂₅H₂₇N₂O₆Cl: C, 61.66; H, 5.54; N, 5.75. Found: C, 61.97; H, 5.76; N, 5.62. Similarly, compounds **21–29** were synthesized from the corresponding ureido derivatives.

(6S)-1-(2-Chlorobenzyl-3-phenyl-5,6-dihydro-6-(1,2-O-isopropylidene-3-O-methyl-α-D-xylo-tetrofuranos-4-yl)uracil (21): Colourless foam, yield 0.24 g (90 %), R_f 0.45 (3:2 hexane/ethyl acetate). [α]_D²⁵ –39.04 (c 0.3125, CHCl₃). MS (FAB): *m/z* 488 (M + H)⁺. IR (Neat) ν_{max}: 3434, 2981, 2244, 1673, 1456, 1374, 1210, 1070, 1012, 858, 758 cm^{–1}. ¹H NMR (CDCl₃): δ 7.47–7.17 (m, 9H, ArH), 5.88 (d, *J* = 3.7 Hz, 1H, H-1'), 5.13 and 4.52 (2 d, *J* = 15.1 Hz, each 1H, NCH_A and NCH_B), 4.59 (d, *J* = 3.7 Hz, 1H, H-2'), 4.37–4.33 (m, 1H, H-4'), 4.00–3.96 (m, 1H, H-6), 3.76 (d, *J* = 3.4 Hz, 1H, H-3'), 3.75 (s, 3H, OCH₃), 3.18 (d, *J* = 16.8 Hz, 1H, H-5_A), 2.85 (dd, *J* = 16.9 and 6.5 Hz, 1H, H-5_B), 1.44 and 1.32 [2 s, each 3H, C(CH₃)₂]. ¹³C NMR (CDCl₃): δ 169.30 (C = O), 154.0 (NC = ON), 136.1, 134.8, 133.9, 131.2, 130.2, 129.7, 129.4, 129.2, 128.6, 127.8 (Ar-C), 112.4 [C(CH₃)₂], 105.4 (C-1), 84.9 (C-2), 81.2 (C-4), 80.1 (C-3), 57.6 (–OCH₃), 51.1 (C-6), 48.7 (–NCH₂), 34.6 (C-5), 27.3 and [C(CH₃)₂] 26.6. Anal. Calcd for C₂₅H₂₇N₂O₆Cl: C, 61.66; H, 5.55; N, 5.75. Found: C, 61.89; H, 5.84; N, 5.32.

(6S)-1-(2-Chlorobenzyl)-3-(4-chlorophenyl)-5,6-dihydro-6-(1,2-O-isopropylidene-3-O-methyl-α-D-xylo-tetrofuranos-4-yl)uracil (22): Colourless foam, yield 0.61 g (95 %), R_f 0.40 (3:2 hexane/ethyl acetate). [α]_D²⁵ –2.66 (c 0.1875, CHCl₃). MS (FAB): *m/z* 522 (M + H)⁺. IR (Neat) ν_{max}: 3403, 2986, 2939, 2377, 1688, 1592, 1458, 1368, 1194, 1077, 1023, 853, 754 cm^{–1}. ¹H NMR (CDCl₃): δ 7.44–7.37 (m, 4H, ArH), 7.25–7.22 (m, 2H, ArH), 7.07 (d, *J* = 8.6 Hz, 2H, ArH), 5.98 (d, *J* = 3.8 Hz, 1H, H-1'), 5.26 and 4.51 (2 d, *J* = 14.2 Hz, each 1H, NCH_A and NCH_B), 4.61 (d, *J* = 3.8 Hz, 1H, H-2'), 4.45 (dd, *J* = 9.9 and 2.7 Hz, 1H, H-4'), 4.02–3.97 (m, 1H, H-6), 3.72 (d, *J* = 2.7 Hz, 1H, H-3'), 3.38 (s, 3H, OCH₃), 3.05 (dd, *J* = 16.9 and 6.5 Hz, 1H, H-5_A), 2.59 (d, *J* = 16.8 Hz, 1H, H-5_B), 1.49 and 1.34 [2 s, each 3H, C(CH₃)₂]. ¹³C NMR (CDCl₃): δ 166.4 (C = O), 150.7 (NC = ON), 132.7, 132.4, 131.9, 129.6, 128.1, 127.9, 127.4, 127.2, 125.0 (Ar-C), 110.1 [C(CH₃)₂], 103.3 (C-1), 81.8 (C-2), 78.9 (C-4), 78.8 (C-3), 55.6 (–OCH₃), 49.2 (C-6), 48.8 (–NCH₂), 35.0 (C-5), 27.2 and 26.5 [C(CH₃)₂]. Anal. Calcd for C₂₅H₂₆N₂O₆Cl₂: C, 57.6; H, 4.99; N, 5.37. Found: C, 57.95; H, 5.03; N, 5.01.

(6S)-3-Benzyl-5,6-dihydro-6-(1,2-O-isopropylidene)-3-O-methyl-α-D-xylo-tetrofuranos-4-yl)-1-(4-methoxybenzyl)-uracil (23): Colourless foam, yield 0.6 g (96 %), R_f 0.40 (3:2 hexane/ethyl acetate). [α]_D²⁵ –25.0 (c 0.2, CHCl₃), MS (FAB): *m/z* 497 (M + H)⁺. IR (Neat) ν_{max}: 3373, 2936, 2366, 1671, 1611, 1382, 1248, 1080, 850, 756 cm^{–1}. ¹H NMR (CDCl₃): δ 7.40–7.30 (m, 3H, ArH), 7.29–7.20 (m, 3H, ArH), 6.88–6.83 (m, 2H, ArH), 5.90 (d, *J* = 3.8 Hz, 1H, H-1'), 5.35 (d, *J* = 15.02 Hz, 1H, N¹CH_A), 5.02 (s, 2H, N³CH₂Ph) 4.53 (d, *J* = 3.8 Hz, 1H, H-2'), 4.14–4.06 (m, 2H, H-4' and N¹CH_B), 3.79 (s, 3H, Ar–OCH₃), 3.76–3.72 (m, 1H, H-6), 3.61 (d, *J* = 3.2 Hz, 1H, H-3'), 3.31 (s, 3H, OCH₃), 2.66 (dd, *J* = 16.8 and 6.78 Hz, 1H, H-5_A), 2.42 (dd, *J* = 16.8 and 1.4 Hz, 1H, H-5_B), 1.27 [s, 6H, –C(CH₃)₂]. ¹³C NMR (CDCl₃): 168.6 (C = O), 159.5 (NC = ON), 153.2, 138.2, 130.1, 129.9, 128.9, 128.9, 127.7, 114.5 (Ar-C), 112.4 [C(CH₃)₂], 105.5 (C-1), 84.2 (C-2), 81.4 (C-4), 80.9 (C-3), 57.8

($-\text{OCH}_3$), 55.7 (Ar- OCH_3), 51.0 (C-6), 49.8, 44.2 ($-\text{NCH}_2$), 34.7 (C-5), 27.1 and 26.6 [$\text{C}(\text{CH}_3)_2$]. Anal. Calcd for $\text{C}_{27}\text{H}_{32}\text{N}_2\text{O}_7$: C, 65.32; H, 6.45; N, 5.64. Found: C, 66.10; H, 7.01; N, 5.50.

(6S)-1-(3,4-Dimethoxybenzyl)-3-phenyl-5,6-dihydro-6-(1,2-O-isopropylidene-3-O-methyl- α -D-xylotetrafurans-4-yl)uracil (24): Colourless foam, yield 0.57 g (90%), R_f 0.35 (3:2 hexane/ethyl acetate). $[\alpha]_D^{25} -14.6$ (c 0.20, $\text{CH}_3\text{COOC}_2\text{H}_5$). MS (FAB): m/z 513 ($\text{M} + \text{H}^+$). IR (Neat) $\nu_{\max}$ cm^{-1} : 3455, 2939, 2370, 1679, 1597, 1454, 1202, 1078, 1019, 755. ^1H NMR (CDCl_3): δ 7.49–7.41 (m, 3H, ArH), 7.18–7.15 (d, $J = 6.5$ Hz, 2 H, ArH), 6.93–6.85 (m, 3H, ArH), 5.98 (d, $J = 3.8$ Hz, 1H, H-1'), 5.37 and 4.21 (2 d, $J = 14.8$ Hz, each 1H, N^1CH_A and N^1CH_B), 4.61 (d, $J = 3.8$ Hz, 1H, H-2'), 4.52 (dd, $J = 9.9$ and 3.1 Hz, 1H, H-4'), 3.92–3.89 (m, 1H, H-6), 3.87 (s, 6H, Ar- OCH_3), 3.71 (d, $J = 3.1$ Hz, 1H, H-3'), 3.38 (s, 3H, OCH_3), 2.85 (dd, $J = 16.8$ and 6.5 Hz, 1H, H-5_A), 2.55 (d, $J = 16.8$ Hz, 1H, H-5_B), 1.52 and 1.35 [2 s, each 3H, $-\text{C}(\text{CH}_3)_2$]. ^{13}C NMR (CDCl_3): 168.7 (C = O), 153.3 (NC = ON), 149.7, 149.2, 135.9, 130.3, 129.6, 129.0, 128.8, 121.4, 112.4, 112.4 (Ar-C), 111.7 [$\text{C}(\text{CH}_3)_2$], 105.5 (C-1), 84.2 (C-2), 81.3 (C-4), 80.9 (C-3), 57.9 ($-\text{OCH}_3$), 56.5, 56.3 (Ar- OCH_3), 51.6 (C-6), 49.9 ($-\text{NCH}_2$), 35.2 (C-5), 27.2, 26.6. Anal. Calcd for $\text{C}_{27}\text{H}_{32}\text{N}_2\text{O}_8$: C, 63.28; H, 6.25; N, 5.46. Found: C, 64.33; H, 6.58; N, 5.31.

(6S)-3-Benzyl-1-(3,4-dimethoxybenzyl)-5,6-dihydro-6-(1,2-O-isopropylidene-3-O-methyl- α -D-xylotetrafurans-4-yl)uracil (25): Colourless foam, yield 0.61 g (95%), R_f 0.45 (3:2 hexane/ethyl acetate). $[\alpha]_D^{25} -22.4$ (c 0.2, $\text{CH}_3\text{COOC}_2\text{H}_5$). MS (FAB): m/z 527 ($\text{M} + \text{H}^+$). IR (Neat) $\nu_{\max}$ cm^{-1} : 3431, 2939, 2378, 2148, 1597, 1521, 1456, 1367, 1260, 1162, 1077, 1023, 700.5, 631, 556 cm^{-1} . ^1H NMR (CDCl_3): δ 7.39–7.33 (m, 2H, ArH), 7.30–7.24 (m, 4H, ArH), 6.82 (s, 2H, ArH), 5.90 (d, $J = 3.8$ Hz, 1H, H-1'), 5.34 and 4.13 (2 d, $J = 14.9$ Hz, each 1H, N^1CH_A and N^1CH_B), 4.54 (s, 2H, $-\text{N}^3\text{CH}_2$), 4.53 (d, $J = 3.8$ Hz, 1H, H-2'), 4.14 (dd, $J = 9.7$ and 3.0 Hz, 1H, H-4'), 3.85 and 3.83 (2 s, each 3H, Ar- OCH_3), 3.74–3.70 (m, 1H, H-6), 3.61 (d, $J = 3.0$ Hz, 1H, H-3'), 3.31 (s, 3H, OCH_3), 2.65 (dd, $J = 16.8$ and 6.7 Hz, 1H, H-5_A), 2.43 (d, $J = 16.8$ Hz, 1H, H-5_B), 1.27 [s, 6H, $-\text{C}(\text{CH}_3)_2$]. ^{13}C NMR (CDCl_3): δ 168.6 (C = O), 158.5 (NC = ON), 149.6, 149.0, 139.7, 130.5, 129.09, 128.9, 128.8, 127.8, 127.6, 127.5, 121.0 (Ar-C), 112.00 [$\text{C}(\text{CH}_3)_2$], 111.7, 111.4 (Ar-C), 105.5 (C-1), 84.1 (C-2), 81.4 (C-4), 80.9 (C-3), 57.7 ($-\text{OCH}_3$), 56.3, 56.2 (Ar- OCH_3), 51.6 (C-6), 49.7, 44.2 ($-\text{NCH}_2$), 34.6 (C-5), 27.1 and 26.5 [$\text{C}(\text{CH}_3)_2$]. Anal. Calcd for $\text{C}_{28}\text{H}_{34}\text{N}_2\text{O}_8$: C, 63.87; H, 6.46; N, 5.32. Found: C, 64.19; H, 6.81; N, 5.11.

(6S)-6-(3-O-Benzyl-1,2-O-isopropylidene- α -D-xylotetrafurans-4-yl)-1-(2-chlorobenzyl)-5,6-dihydro-3-phenyluracil (26): Colourless foam, yield 0.55 g (85%), R_f 0.35 (3:2 hexane/ethyl acetate). $[\alpha]_D^{20} -25.6$ (c 0.1875, CHCl_3). MS (FAB): m/z 564 ($\text{M} + \text{H}^+$). IR (Neat) $\nu_{\max}$ cm^{-1} : 2927, 2371, 1682, 1597 cm^{-1} . ^1H NMR (CDCl_3): δ 7.42–7.32 (m, 8H, ArH), 7.25–7.19 (m, 4H, ArH), 7.14–7.10 (m, 2H, ArH), 6.01 (d, $J = 3.7$ Hz, 1H, H-1'), 5.26 (d, $J = 14.9$ Hz, 1H, NCH_AAr), 4.70 and 4.58 (2 d, $J = 11.9$ Hz, each 1H, $-\text{OCH}_A\text{Ph}$ and $-\text{OCH}_B\text{Ph}$), 4.65 (d, $J = 3.7$ Hz, 1H, H-2'), 4.51–4.43 (m, 2H, H-4' and $-\text{NCH}_B\text{Ar}$), 4.21–4.15 (m, 1H, H-6), 3.95 (d, $J = 3.1$ Hz, 1H, H-3'), 2.92 (dd, $J = 16.9$ and 5.6 Hz, 1H, H-5_A), 2.32 (d, $J = 16.9$ Hz, 1H, H-5_B), 1.51 and 1.33 [2 s, each 3H, $\text{C}(\text{CH}_3)_2$]. ^{13}C NMR (CDCl_3): δ 168.7 (C = O), 153.3 (NC = ON), 137.1, 135.8, 135.2,

134.3, 132.2, 130.1, 129.5, 129.5, 129.1, 129.0, 128.7, 128.0, 127.3 (Ar-C), 112.5 [C(CH₃)₂], 105.7 (C-1), 81.9 (C-2), 81.1 (C-4), 81.3 (C-3), 72.2 (–OCH₂Ph), 51.3 (C-6), 51.2 (–NCH₂), 34.7 (C-5), 27.2 and 26.6 [C(CH₃)₂]. Anal. Calcd for C₃₁H₃₁N₂O₆Cl: C, 66.13; H, 5.51; N, 4.97. Found: C, 66.46; H, 5.72; N, 4.83.

(6S)-6-(3-O-Benzyl-1,2-O-isopropylidene- α -D-xylo-tetrofuranos-4-yl)-3-(4-chlorophenyl)-5,6-dihydro-1-(4-methoxybenzyl)uracil (27): Colourless foam, yield 0.58 g (90 %), R_f 0.35 (3:2 hexane/ethylacetate). [α]_D²⁵ –4.36 (c 0.1375, CHCl₃). MS (FAB) *m/z* = 593 (M + H)⁺. IR (Neat) $\nu_{\max}$: 3450, 2931, 2374, 1678, 1603, 1509 cm^{–1}. ¹H NMR (CDCl₃): δ 7.39 (d, *J* = 8.6 Hz, 2H, ArH), 7.34–7.18 (m, 7H, ArH), 7.07 and 6.87 (2 d, *J* = 8.6 Hz, each 2H, ArH), 6.0 (d, *J* = 3.7 Hz, 1H, H-1'), 5.33 and 4.20 (2 d, *J* = 14.8 Hz, each 1H, NCH_AAr and NCH_BAr), 4.68 (d, *J* = 11.9 Hz, 1H, OCH_APh), 4.64 (d, *J* = 3.7 Hz, 1H, H-2'), 4.45–4.39 (m, 2H, OCH_BPh and H-4'), 3.93–3.89 (m, 2H, H-6 and H-3'), 3.80 (s, 3H, ArOCH₃), 2.65 (dd, *J* = 16.9 and 6.5 Hz, 1H, H-5_A), 2.26 (d, *J* = 16.9 Hz, 1H, H-5_B), 1.49 and 1.33 [2 s, each 3H, C(CH₃)₂]. ¹³C NMR (CDCl₃): δ 168.5 (C = O), 159.7 (NC = ON), 153.0, 136.9, 134.6, 134.4, 130.4, 130.4, 129.7, 129.6, 129.1, 128.8, 128.1, 114.6 (Ar-C), 112.5 [C(CH₃)₂], 105.6 (C-1), 81.8 (C-1), 81.7 (C-1), 81.3 (C-1), 72.2 (–OCH₂Ph), 55.7 (Ar–OCH₃), 51.4 (C-6), 49.5 (–NCH₂), 34.9 (C-5), 27.2 and 26.6 [C(CH₃)₂]. Anal. Calcd for C₃₂H₃₃N₂O₇Cl: C, 64.81; H, 5.57; N, 4.72. Found: C, 65.19; H, 5.94; N, 4.68.

(6S)-6-(3-O-Benzyl-1,2-O-isopropylidene- α -D-xylo-tetrofuranos-4-yl)-1-(3,4-dimethoxybenzyl)-5,6-dihydro-3-phenyluracil (28): Colourless foam, yield 0.41 g (90 %), R_f 0.35 (3:2 hexane/ethyl acetate). MS (FAB): *m/z* 589 (M + H)⁺. IR (Neat) $\nu_{\max}$: 3433, 2263, 1670, 1594, 1503, 1425, 1387, 1248, 1155, 1062, 1003, 875, 821 cm^{–1}. ¹H NMR (CDCl₃): δ 7.44–7.31 (m, 5H, ArH), 7.21–7.12 (m, 5H, ArH), 6.87–6.84 (m, 3H, ArH), 6.01 (d, *J* = 3.7 Hz, 1H, H-1'), 5.30 and 4.22 (2 d, *J* = 14.7 Hz, each 1H, NCH_A and NCH_B), 4.67 and 4.43 (2 d, *J* = 11.7 Hz, each 1H, OCH_APh and OCH_BPh), 4.65 (d, *J* = 3.7 Hz, 1H, H-2'), 4.49 (dd, *J* = 9.9 and 3.0 Hz, 1H, H-4'), 3.95 (m, 1H, H-6), 3.96–3.92 (m, 2H, H-6 and H-3'), 3.87 and 3.83 (2 s, each 3H, ArOCH₃), 2.69 (dd, *J* = 16.9 and 6.5 Hz, 1H, H-5_A), 2.30 (d, *J* = 16.9 Hz, 1H, H-5_B), 1.51 and 1.33 [2 s, each 3H, C(CH₃)₂]. ¹³C NMR (CDCl₃): δ 168.5 (C = O), 153.0 (NC = ON), 149.7, 149.2, 135.9, 137.0, 130.3, 129.5, 129.1, 129.0, 128.9, 128.8, 128.7, 128.5, 128.3, 128.1, 121.6, 112.5, 112.5 (Ar-C), 111.8 [C(CH₃)₂], 105.6 (C-1), 81.9 (C-2), 81.7 (C-4), 81.4 (C-3), 72.2 (–OCH₂Ph), 56.4, 56.3 (Ar–OCH₃), 51.7 (C-6), 49.4 (–NCH₂), 34.9 (C-5), 27.2, 26.6. Anal. Calcd for C₃₃H₃₆N₂O₈: C, 67.34; H, 6.12; N, 4.76. Found: C, 67.67; H, 6.35; N, 4.62.

(6S)-3-(3-Acetylphenyl)-6-(3-O-benzyl-1,2-O-isopropylidene- α -D-xylo-tetrofuranos-4-yl)-1-(3,4-dimethoxybenzyl)-5,6-dihydrouracil (29): Colourless foam; yield 0.42 g (89 %), R_f 0.3 (3:2 hexane/ethyl acetate). [α]_D²⁵ + 33 (c 0.1, CHCl₃). MS (FAB): *m/z* 631 (M + H)⁺. IR (Neat) $\nu_{\max}$: 3018, 2438, 1681, 1597, 1513 cm^{–1}. ¹H NMR (CDCl₃): δ 7.97 (d, *J* = 7.8 Hz, 1H, ArH), 7.73 (s, 1H, ArH), 7.51 (dd, *J* = 7.8 and 7.31 Hz, 1H, ArH), 7.37–7.21 (m, 4H, ArH), 7.23–7.19 (m, 2H, ArH), 6.88–6.85 (m, 3H, ArH), 6.03 (d, *J* = 3.6 Hz, 1H, H-1'), 5.34 and 4.21 (2 d, *J* = 14.7 Hz, each 1H, NCH_AAr and NCH_BAr), 4.70 and 4.42 (2 d, *J* = 11.7 Hz, each 1H, OCH_APh and OCH_BPh), 4.67 (d, *J* = 3.6 Hz, 1H, H-2'), 4.47 (dd, *J* = 9.1 and 2.8 Hz, 1H, H-4'), 4.03–3.97 (m, 1H, H-6), 3.95 (d, *J* = 2.8 Hz, 1H, H-3'), 3.88 and 3.84 (2 s, each 3H,

ArOCH₃), 2.70 (dd, $J = 16.9$ and 6.5 Hz, 1H, H-5_A), 2.58 (s, 3H, ArCOCH₃), 2.30 (d, $J = 16.9$ Hz, 1H, H-5_B), 1.53 and 1.35 [2 s, each 3H, C(CH₃)₂]. ¹³C NMR (CDCl₃): δ 197.1 (C = OCH₃), 168.5 (C = O), 153.0 (NC = ON), 149.6, 149.2, 138.5, 136.9, 136.3, 133.8, 129.8, 129.2, 129.1, 128.8, 128.6, 128.1, 121.6 (Ar-C), 112.4 [C(CH₃)₂], 111.7, 112.6 (Ar-C), 105.7 (C-1), 81.3 (C-2), 81.7 (C-4), 81.3 (C-3), 72.2 (–OCH₂Ph), 56.3, 56.4 (Ar–OCH₃), 51.8 (C-6), 49.4, 34.9 (C-5), 27.2, 27.0, 26.6. Anal. Calcd for C₃₅H₃₈N₂O₉ : C, 66.66; H, 6.03; N, 4.44. Found: C, 66.92; H, 6.32; N, 4.39.

ACKNOWLEDGMENTS

Authors thank Director, CDRI for his keen interest in the programme, and to ICMR, New Delhi & V.W. Foundation Germany for financial support. We thank RSIC Division for giving spectral data and analysis. This paper bears CDRI communication No. 6338.

REFERENCES

- Juaristi, E.; Quintana, D.; Balderas, M.; Garcia-Perez, E. Enantioselective synthesis of β -amino acids. *Tetra. Assym.* **1996**, 7, 2233–2241, and references cited therein.
- Chu, K.S.; Negrete, G.R.; Konopelski, J.P.; Lakner, F.J.; Woo, N.T.; Olmstead, M.M. Enantiomerically pure dihydropyrimidinones as reagents and auxiliaries for asymmetric synthesis. *J. Am. Chem. Soc.* **1992**, 114, 1800–1802.
- Burchenal, J.H.; Ciovacco, K.; Kalhar, K.; O. Toole, T.; Kiefner, R.; Dowing, M.D.; Chu, C.K.; Watanabe, K.A.; Wempen, I.; Fox, J.J. Antilekemic effects of pseudoisocytidine a new synthetic pyrimidine C-nucleoside. *Cancer Res.* **1976**, 36, 1520–1523.
- Suhadolnik, R.J. *Nucleoside Antibiotics*; Wiley Inter Science: New York, NY, 1970.
- Postema, M.H.D. *C-Glycoside Synthesis*; CRC: London, 1995.
- Levy, D.E.; Tang, C. *The Chemistry of C-Glycosides*; Elsevier: Oxford, 1995.
- Schaeffer, H.J.; Beauchamp, L.; Miranda, P.D.; Elion, G.B.; Bauer, D.J.; Collins, P. 9-(2-hydroxy ethoxymethyl) guanine activity against viruses of the herpes group. *Nature* **1978**, 272, 583–585.
- Skaric, V.; Matulic-Adamic, J. Synthesis of β -D-arabinofuranos[1',2':4',5'] oxa(thia)zolidines. *J. Chem. Soc., Perkin Trans.* **1985**, 1, 779–781.
- Skaric, V.; Gaspert, B.; HohnJee, M.; Lacan, G. Some dihydro-cytidines and isocytidines. *J. Chem. Soc., Perkin Trans.* **1974**, 1, 267–271.
- Robins, R.K.; Srivastava, P.C.; Narayana, V.L.; Plowman, J.; Paul, K.D. 2- β -D-ribofuranosylthiazole-4-carboxamide, a novel potential antitumor agent for lung tumors and metastases. *J. Med. Chem.* **1982**, 25, 107–108.
- Postema, M.H.D. Synthesis of some unnatural C-nucleoside. *Tetrahedron* **1992**, 40, 8545–8552.
- Watanabe, K.A. *Chemistry of Nucleosides and Nucleotides*; Townsend, L.B., Ed.; Plenum Press: New York, 1994; Vol. 3, 421–535.
- Lankner, F.J.; Chu, K.S.; Negrete, G.R.; Konopelski, J.P. Synthesis of



- enantiomerically pure β -amino acids from 2-*tert*-butyl-1-carbomethoxy-2,3-dihydro-4(1H)-pyrimidinone: (*R*)-3-Amino-3-(*p*-methoxy phenyl) propionic acid (1(2H)-pyridine carboxylic acid, 2-(1,1-dimethyl ethyl)-3,4-dihydro-4-oxo-, methyl ester, (*R*)- or (*S*)-. *Org. Synth.* **1996**, 73, 201–214.
14. Jaramillo, C.; Knapp, S. Synthesis of C-aryl glycosides. *Synthesis* **1994**, 1–20.
 15. Chu, C.K.; Wempen, I.; Watanabe, K.A.; Fox, J.J. General synthesis of pyrimidine-C-5-nucleosides related to pseudouridine. Synthesis of 5-(β -D-ribofuranosyl) isocytosine (pseudoisocytidine), 5-(β -D-ribofuranosyl)-2-thio uracil (2-thiopseudouridine) and 5-(β -D-ribofuranosyl) uracil (pseudouridine). *J. Org. Chem.* **1976**, 41, 2793–2801. and references cited therein.
 16. Guianvarc'h, D.; Fourrey, J.L.; Dau, M.E.T.H.; Guerinéau, V. Stereocontrolled synthesis of heterocyclic C-nucleosides, protecting group effect and molecular modelling studies. *J. Org. Chem.* **2002**, 67, 3724–3729.
 17. Fuentes, J.; Angulo, M.; Pradera, M.A. Fluoro nucleosides, isothiocyanato-C-nucleoside and thiouridine di-C-nucleosides via cyclic sulphates. *J. Org. Chem.* **2002**, 67, 2577–2583.
 18. Lankner, F.J.; Negrette, G.R. A new and convenient chiral auxiliary for symmetric diels-alder cycloaddition in environmentally benign solvents. *Synlett* **2002**, 643–644.
 19. Tripathi, R.P.; Tripathi, R.; Tiwari, V.K.; Bala, L.; Sinha, S.; Srivastava, R.; Srivastava, B. S synthesis of glycosylated β -amino acids as new class of antitubercular agents. *Eur. J. Med. Chem.* **2002**, 37, 773.
 20. Khan, A.R.; Tripathi, R.P.; Tiwari, V.K.; Mishra, R.C.; Reddy, V.J.M.; Saxena, J.K. Conjugate addition of amines to sugar derived olefinic ester: synthesis of glycosylated amino esters as DNA topoisomerase –II inhibitors. *J. Carbohydr. Chem.* **2002**, 21 (6), 587–600, and references cited in.
 21. Mishra, R.C.; Tewari, N.; Arora, K.; Tripathi, R.P.; Tiwari, V.K.; Walter, R.D.; Srivastava, A.K. DBU assisted cyclorelease elimination: combinatorial synthesis and γ -glutamyl cystein synthetase & glutathione-S-transeferase modulatory activity of C-nucleoside analogs. *Comb. Chem. High Throughput Screen.* **2003**, 6, 37–50.
 22. Tewari, N.; Tiwari, V.K.; Mishra, R.C.; Tripathi, R.P.; Ahmed, R.; Srivastava, A.; Srivastava, R.; Srivastava, B.S. Synthesis and bioevaluation of glycosyl ureas as α -glucosidase inhibitors and antituberculosis agents. *Bioorganic Med Chem.* **2003**, 11, 2911–2922.
 23. Tewari, N.; Mishra, R.C.; Tiwari, V.K.; Tripathi, R.P. DBU/TBAB/4A⁰ Catalysed cyclatic amidation reactions: a highly efficient & convenient synthesis of C-Nucleosides. *Synlett* **2002**, 11, 1779–1781.
 24. Patil, N.T.; Tilekar, J.N.; Dhavale, D.D. Intermolecular Michael addition of substituted amines to a sugar derived α,β -unsaturated ester: Synthesis of 1-deoxy-D-glucosyl and L-ido homonojirimycin-1-deoxy-castanospermine and 1-deoxy-8a-epicastanospermine. *J. Org. Chem.* **2001**, 66, 1065–1071, and references cited therein.

Received June 6, 2003

Accepted November 19, 2003



Request Permission or Order Reprints Instantly!

Interested in copying and sharing this article? In most cases, U.S. Copyright Law requires that you get permission from the article's rightsholder before using copyrighted content.

All information and materials found in this article, including but not limited to text, trademarks, patents, logos, graphics and images (the "Materials"), are the copyrighted works and other forms of intellectual property of Marcel Dekker, Inc., or its licensors. All rights not expressly granted are reserved.

Get permission to lawfully reproduce and distribute the Materials or order reprints quickly and painlessly. Simply click on the "Request Permission/Order Reprints" link below and follow the instructions. Visit the [U.S. Copyright Office](#) for information on Fair Use limitations of U.S. copyright law. Please refer to The Association of American Publishers' (AAP) website for guidelines on [Fair Use in the Classroom](#).

The Materials are for your personal use only and cannot be reformatted, reposted, resold or distributed by electronic means or otherwise without permission from Marcel Dekker, Inc. Marcel Dekker, Inc. grants you the limited right to display the Materials only on your personal computer or personal wireless device, and to copy and download single copies of such Materials provided that any copyright, trademark or other notice appearing on such Materials is also retained by, displayed, copied or downloaded as part of the Materials and is not removed or obscured, and provided you do not edit, modify, alter or enhance the Materials. Please refer to our [Website User Agreement](#) for more details.

[Request Permission/Order Reprints](#)

Reprints of this article can also be ordered at

<http://www.dekker.com/servlet/product/DOI/101081NCN120030712>